Table 2.

Somatic Growth at P21

	RA				IH
	Topical ocular		Oral		Topical ocular		Oral
	Sal	Prop	Saline	Prop	Saline	Prop	Saline	Prop
% Change body wt. (P0–P21)	350.1 ± 14.4	429.1 ± 14.5**	475.1 ± 32.4##	482.3 ± 7.2##	514.0 ± 11.6§§	532.0 ± 22.1§§	388.0 ± 21.3##§§	458.6 ± 11.3**##
% Change length (P0–P21)	84.6 ± 1.4	95.2 ± 4.1*	97.4 ± 3.6##	99.7 ± 1.2	84.1 ± 2.2	84.9 ± 2.2§	73.1 ± 1.8##§§	79.1 ± 1.2#§§
Brain/body wt. ratio	0.041 ± 0.001	0.034 ± 0.001**	0.034 ± 0.002##	0.03 ± 0.0006	0.052 ± 0.001§§	0.056 ± 0.001§§	0.039 ± 0.001##	0.034 ± 0.0009**##
Heart/Body wt. ratio	0.006 ± 0.004	0.006 ± 0.0003	0.005 ± 0.0002	0.006 ± 0.0006	0.01 ± 0.0003§§	0.01 ± 0.004§§	0.007 ± 0.0003##	0.005 ± 0.0002**##
Lung/body wt. ratio	0.01 ± 0.0004	0.01 ± 0.0005	0.01 ± 0.001	0.01 ± 0.0005	0.019 ± 0.0002§§	0.019 ± 0.005§§	0.013 ± 0.0003##	0.012 ± 0.0004##
Liver/body wt. ratio	0.034 ± 0.002	0.037 ± 0.002	0.039 ± 0.002	0.03 ± 0.002*#	0.067 ± 0.003	0.061 ± 0.003§§	0.035 ± 0.002##§§	0.034 ± 0.001##
Kidney/body wt. ratio	0.013 ± 0.0006	0.012 ± 0.0006	0.012 ± 0.0006	0.013 ± 0.0002	0.021 ± 0.0006§§	0.019 ± 0.0005*§§	0.011 ± 0.0006##	0.012 ± 0.0004##

^*P < 0.05, ^**P < 0.01 saline versus propranolol; ^#P < 0.05, ^##P < 0.01 topical ocular versus oral ^§P < 0.05, ^§§P < 0.01 RA vs. IH (n = 18 pups/group).